Valsartan

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

CAS number: 137862-53-4

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The active ingredient valsartan, belongs to the Sartane family. Valsartan is orally active and belongs to the specific (selective) angiotensin II receptor antagonists (AT1 receptor inhibitors).

Dosage and method of useThis section has been translated automatically.

Valsartan should be dosed gradually. The daily dose is 40 to a maximum of 320 mg.

Undesirable effectsThis section has been translated automatically.

Some of the most common side effects of valsartan are:

  • upper respiratory infections and flu-like symptoms and gastrointestinal problems. Headache, dizziness and inflammation of the throat, conjunctiva or joints are other side effects of valsartan. In severe cases, unconsciousness or heart failure may occur. Valsartan may also cause depression and sleep disturbances.

More rare are:

  • Vertigo
  • Cough
  • Abdominal pain
  • Exhaustion.

Side effects with unknown frequency:

  • Decreased hemoglobin
  • hematocrit drop
  • Neutropenia
  • thrombocytopenia
  • Hypersensitivity including serum sickness
  • Pseudolymphomas (Sawada Yet al. 2010)
  • Sprue-like enteropathy (see olmesartan below)

Note(s)This section has been translated automatically.

After oral uptake, the active substance reaches peak concentrations in the plasma after 2 - 4 hours. The mean absolute bioavailability is 23 %. In contrast to other sartans such as losartan, the bioavailability of valsartan is rather low at 25 %. valsartan is excreted primarily biliarily with the feces (approx. 83 % of the dose) and renally to approx. 13 %. The half-life of valsartan is 9 hours.

Authors

Last updated on: 29.10.2020